News

Public · Published

Notable healthcare headlines for the week: Eli Lilly, Merck, and AstraZeneca in focus

For the reported week, the S&P 500 Health Care Sector Index gained 3.08%, while the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average fell. Eli Lilly rose 11.31% and reported strong third-quarter sales led by Mounjaro and Zepbound, raising its full-year 2026 revenue outlook.

Published:

Updated:

What happened

For the reported week, the S&P 500 Health Care Sector Index gained 3.08%, while the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average fell. Eli Lilly rose 11.31% and reported strong third-quarter sales led by Mounjaro and Zepbound, raising its full-year 2026 revenue outlook.

Confirmed

Global impact / market context

Lilly’s results connect demand for its diabetes and weight-loss medicines to higher reported revenue and a stronger full-year outlook. If that demand continues, it could support sales growth; the healthcare sector’s weekly gain while broad indexes fell also shows a contrasting performance during the period.

Analyst inference

The article describes a week of technology-stock selling after discouraging earnings reports, with all three major U.S. indexes lower. Healthcare moved in the opposite direction, gaining 3.08%; Lilly and Regeneron were among the sector’s leading weekly gainers, while several other healthcare stocks declined.

Confirmed

What to watch

  1. Watch for Lilly’s next reported sales and outlook: sustained demand for Mounjaro and Zepbound would indicate whether these medicines continue driving the revenue growth described. Analyst inference
  2. Compare healthcare’s performance with broad indexes in subsequent reporting periods; this article documents one week of divergence, not evidence that the pattern will continue. Analyst inference
  3. The article says Lilly raised its full-year 2026 revenue outlook, but provides no updated forecast amount; a later report could clarify the scale of the revision. Confirmed

Evidence